BERLIN and BOSTON, Oct. 24, 2024 (GLOBE NEWSWIRE) — Bayer has entered into an exclusive licensing agreement with Dewpoint Therapeutics, Inc. for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. This is the first option exercise under the research collaboration between Bayer and Dewpoint Therapeutics, Inc., which began in November 2019.It leverages Dewpoint’s proprietary platform for biomolecular condensates and Bayer’s small molecule R&D capabilities to develop new treatments for cardiovascular and renal diseases.